Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma

Wheatley‐Price, Paul; Yang, Baoming; Patsios, Demetris; Patel, Devalben; Ma, Clement; Xu, Wengui; Leighl, Natasha B.; Feld, Ronald; Cho, B.C. John; O'Sullivan, Brenda; Roberts, Heidi C.; Tsao, Ming‐Sound; Tammemägi, M.; Anraku, Masaki; Chen, Zhuo; Perrot, Marc de; Liu, Geoffrey

doi:10.1200/jco.2009.26.9944

Cited by 96 publications

(91 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant association was observed between the response outcome and the relative change in mesothelin levels in 21 patients receiving chemotherapy [37]. This was further supported by CREANEY et al [38], who demonstrated that a decrease in serum mesothelin levels following chemotherapy increases the likelihood that the tumour is responding to therapy and that it also predicts for improved survival independent of age, sex, histology and treatment.…”

Section: Treatment Monitoring Performancesupporting

confidence: 66%

“…Mesothelin levels fall with tumour resection and rise with its progression [17]. Measurement of mesothelin may be useful in monitoring treatment response [26,[35][36][37]. Two recent studies suggested that a 10% change in mesothelin levels above baseline values is significant [36,37], whereas others proposed a threshold of 25% [38].…”

Section: Treatment Monitoring Performancementioning

confidence: 99%

“…Measurement of mesothelin may be useful in monitoring treatment response [26,[35][36][37]. Two recent studies suggested that a 10% change in mesothelin levels above baseline values is significant [36,37], whereas others proposed a threshold of 25% [38]. HOLLEVOET et al [39] suggested a 15% threshold to avoid interference with ELISA variance, which can be up to 12%.…”

Section: Treatment Monitoring Performancementioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

et al. 2012

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive tumour with poor prognosis whose early diagnosis is difficult. Mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin have attracted attention as biomarkers. The aim of the present review is to provide an overview regarding these candidate biomarkers for MM, and discuss their potential role in today's clinical practice.Mesothelin and MPF have good specificity but sub-optimal sensitivity for detection of MM, being negative both in the sarcomatoid histological sub-type and in almost half of epithelioid mesothelioma, especially in the early stages. Osteopontin is a marker of the duration of asbestos exposure, but lacks specificity for mesothelioma. Several patient characteristics influence the diagnostic accuracy of biomarkers and make the establishment of the ''optimal'' diagnostic threshold difficult. Mesothelin and MPF have proved useful in assessing response to treatment. Combining different markers together may lead to an improvement in diagnostic accuracy, but there is still need for research in this area. Extensive validation and further research is required to improve the use of serum markers in mesothelioma management. In the near future, their application in clinical practice is probably in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.

show abstract

Section: Treatment Monitoring Performancesupporting

confidence: 66%

Section: Treatment Monitoring Performancementioning

confidence: 99%

Section: Treatment Monitoring Performancementioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Numerous studies have reported increased SMRP to be an independent prognostic factors for mesothelioma, with mesothelin levels negatively correlating with survival 31,36,37,63,71,74 . Another area of application of serum mesothelin measurement is monitoring of mesothelioma progression and its response to therapy, with SMRP being increased in disease progression and stable or decreasing SMRP levels being a sign of positive response to therapy 30,53,63,64,70,71,79 .…”

Section: Discussionmentioning

confidence: 99%

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Jakubec¹,

Pelclová²,

Smolková³

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Aims. Pleural mesothelioma is a highly aggressive and difficult-to-treat form of cancer induced by asbestos in 80-90% of cases. The population group most at risk of the condition are asbestos-exposed workers. Mesothelin or soluble mesothelin-related protein (SMRP) is studied as a potential marker of mesothelioma in the at-risk population. Methods. The study comprised 239 subjects with a mean duration of occupational exposure to asbestos of 19.9 years. In all of them, a complete medical history was taken, focused on exposure duration and a physical examination, a chest X-ray or other imaging investigations and a lung function test were performed. Their serum SMRP levels were measured and biopsy samples were taken to diagnose pleural disease. Based on the above examinations, the subjects were classified into subgroups and serum SMRP concentrations were statistically analyzed with respect to individual parameters. Results. In asbestos-exposed individuals, mesothelin levels were significantly higher in those with pathological X-ray findings than in those with normal X-ray results (0.78 ± 0.63 vs. 0.50 ± 0.35, P<0.0001). The group of patients with benign disease had statistically significantly higher mesothelin levels than those with normal X-ray findings (0.755 ± 0.543 vs. 0.50 ± 0.35, P<0.001). In the group with present malignant processes, mesothelin levels were higher than in individuals with benign disease (1.19 ± 0.89 vs. 0.76 ± 0.54, P=0.015). Only a weak correlation was found between mesothelin levels and asbestos exposure duration. There were relatively high sensitivity and high specificity (75% and 90.6%, respectively) of serum mesothelin for pleural mesothelioma. However, given the small number of mesothelioma cases in the group, the results cannot be considered as statistically significant. Conclusions. In persons followed up for asbestos exposure, increased mesothelin levels signalize pathological processes in the chest and correlate with severity of the disease. The study suggests that mesothelin cannot be considered a reliable marker for the early stage of malignant degeneration of pleural disease but only an additional criterion for examination of the followed-up individuals.

show abstract

“…Other studies (8)(9)(10)(11)(12)(13)(14) confirmed that serum SMRP was a promising marker for diagnosis, prognosis and clinical monitoring of MPM. High SMRP concentrations were detected in all the studies only in the epithelioid and mixed MPM.…”

Section: Soluble Mesothelin-related Peptides (Smrp)mentioning

confidence: 87%

Serum mesothelin and other biomarkers: what have we learned in the last decade?

et al. 2018

View full text Add to dashboard Cite

In the last decade there is been much interest in noninvasive, economic and well-accepted diagnostic tests for screening of subjects exposed to asbestos, and in patients with malignant pleuric mesothelioma (MPM) for diagnosis or monitoring response to treatment. Several biomarkers have been suggested as tools for screening and early diagnosis of MPM. Currently, in patients with MPM, have been reported high levels of soluble mesothelin-related peptides (SMRP), plasmatic osteopontin (pOPN), vimentin, fibulin-3 and many others as promising marker for diagnosis, even their use in prevention monitoring is still discussed. In this type of disease, a key role could be played by miRNAs, which expression has been investigated in a large series of MPM to examine new pathways useful in diagnosis, prognosis and therapy. An altered expression of some proteins has been reported, useful as biomarkers, in comparative proteomic analysis of malignant pleural mesothelioma. New promising markers are nowadays under study and alone or better in combination, they'll be very helpful in diagnosing, monitoring mesothelioma patients or for screening of risk groups.

show abstract

Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma

Abstract: Percentage changes in SMRP levels, but not changes in OP levels, are a potentially useful marker of disease course. These findings should be validated prospectively for a role as an objective adjunctive measure of disease course in both clinical trials and clinical practice.

Cited by 96 publications

References 15 publications

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma

Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic

Serum mesothelin and other biomarkers: what have we learned in the last decade?

Contact Info

Product

Resources

About